These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16443406)

  • 1. Adherence and persistence: impact on outcomes and health care resources.
    Reginster JY
    Bone; 2006 Feb; 38(2 Suppl 2):S18-21. PubMed ID: 16443406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring osteoporosis treatment.
    Compston J
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):781-8. PubMed ID: 19945689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
    Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
    Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitated bone mineral density testing versus hospital-based case management to improve osteoporosis treatment for hip fracture patients: additional results from a randomized trial.
    Morrish DW; Beaupre LA; Bell NR; Cinats JG; Hanley DA; Harley CH; Juby AG; Lier DA; Maksymowych WP; Majumdar SR
    Arthritis Rheum; 2009 Feb; 61(2):209-15. PubMed ID: 19177538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education.
    Fitch MI; Maxwell C
    Oncol Nurs Forum; 2008 Jul; 35(4):709-13. PubMed ID: 18591175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
    Cotté FE; Fautrel B; De Pouvourville G
    Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of bone health and osteoporosis risk.
    Eastell R; Hannon RA
    Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.